Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2023. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3678001013 | Dehydrocholic acid 180 mg and pancreatin 300 mg and simeticone 40 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3678002018 | Dehydrocholic acid 180 mg and pancreatin 300 mg and simethicone 40 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3678003011 | Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Is a | Product containing dehydrocholic acid (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Is a | Product containing pancreatin | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has active ingredient | Pancreatin (substance) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has active ingredient | Dehydrocholic acid (substance) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has active ingredient | Bile | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Is a | Product containing simeticone (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has active ingredient | Simeticone | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has manufactured dose form | Tablet | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has manufactured dose form | Oral tablet | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Is a | Product manufactured as oral dose form (product) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has active ingredient | Simeticone | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Simeticone | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 40 | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has active ingredient | Pancreatin (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Pancreatin (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 300 | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has active ingredient | Dehydrocholic acid (substance) | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Dehydrocholic acid (substance) | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 180 | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Pancreatin (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 300 | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Dehydrocholic acid (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 180 | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Simeticone | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 40 | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has unit of presentation | Tablet (unit of presentation) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has precise active ingredient | Simeticone | false | Inferred relationship | Some | 3 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Is a | Product containing dehydrocholic acid and pancreatin and simeticone in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has precise active ingredient | Pancreatin (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has precise active ingredient | Dehydrocholic acid (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Count of base of active ingredient | 3 | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Is a | Product containing only dehydrocholic acid and pancreatin and simeticone in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Plays role | Digestant therapeutic role (role) | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Concept inactivation indicator reference set
FHIR